Literature DB >> 21828182

Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Sylvia Chen1, Matthew J Webber, Jean-Pierre Vilardaga, Ashok Khatri, Dennis Brown, Dennis A Ausiello, Herbert Y Lin, Richard Bouley.   

Abstract

The vasopressin receptor type 2 (V2R) is the major target of vasopressin (VP) in renal epithelial cells. Although it is known that VP induces V2R internalization, accumulation in the perinuclear area, and degradation, the V2R intracellular trafficking pathways remain elusive. We visualized this process by developing a new fluorescent VP analog tagged by tetramethylrhodamine (TMR)-[Lys-(PEG)(2)-Suc-TMR(8)]VP or (VP(TMR)). This ligand is fully functional as revealed by its high binding affinity toward V2R [(K(d)) =157 ± 52 nM] and ability to increase intracellular cAMP 32-fold. VP(TMR) induced V2R internalization in LLC-PK1 cells expressing either a FLAG-tagged receptor (FLAG-V2R) or V2R C-terminally tagged with green fluorescent protein (GFP) (V2R-GFP). After internalization, VP(TMR) and V2R-GFP colocalized in the perinuclear area, suggesting that the hormone and receptor traffic along the same pathway. VP(TMR) and V2R colocalized initially with the early endosome markers EEA1 and Rab5, and later with the recycling and late endosome markers Rab11 and Rab25. Epifluorescence microscopy of LLC-PK1 cells expressing GFP-tagged microtubules (MT) showed that VP(TMR)-containing vesicles travel along the MT network, and even remain attached to MT during the metaphase and anaphase of mitosis. Colchicine, a MT-depolymerizing agent, abolished perinuclear accumulation of VP(TMR), and Western blot analysis showed that VP-induced V2R-GFP degradation is markedly retarded, but not abolished, by colchicine (10 μM). We conclude that the new VP(TMR) ligand is suitable for dissecting V2R and VP internalization and trafficking in cells, and that V2R trafficking and down-regulation is an MT-dependent mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21828182      PMCID: PMC3176653          DOI: 10.1210/en.2011-1049

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  66 in total

1.  Structure and expression of a human oxytocin receptor.

Authors:  T Kimura; O Tanizawa; K Mori; M J Brownstein; H Okayama
Journal:  Nature       Date:  1992-04-09       Impact factor: 49.962

2.  Agonist-induced endocytosis of rat somatostatin receptor 1.

Authors:  Dirk Roosterman; Oliver J Kreuzer; Nicole Brune; Graeme S Cottrell; Nigel W Bunnett; Wolfgang Meyerhof; Martin Steinhoff
Journal:  Endocrinology       Date:  2006-12-14       Impact factor: 4.736

3.  Vasopressin receptor subtypes: autoradiographic localization of V1 vasopressin binding sites in rat brain and kidney.

Authors:  F Fahrenholz; R Gerstberger
Journal:  J Protein Chem       Date:  1989-06

4.  N- and C-terminal structure-activity study of angiotensin II on the angiotensin AT2 receptor.

Authors:  R Bouley; J Pérodin; H Plante; L Rihakova; S G Bernier; L Maletínská; G Guillemette; E Escher
Journal:  Eur J Pharmacol       Date:  1998-02-19       Impact factor: 4.432

5.  Vasopressin receptor-mediated endocytosis in cells transfected with V1-type vasopressin receptors.

Authors:  W Lutz; M Sanders; J Salisbury; S Lolait; A M O'Carroll; R Kumar
Journal:  Kidney Int       Date:  1993-04       Impact factor: 10.612

6.  Internalization of vasopressin analogs in kidney and smooth muscle cells: evidence for receptor-mediated endocytosis in cells with V2 or V1 receptors.

Authors:  W Lutz; M Sanders; J Salisbury; R Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Localization and expression of a collecting duct water channel, aquaporin, in hydrated and dehydrated rats.

Authors:  T Yamamoto; S Sasaki; K Fushimi; K Kawasaki; E Yaoita; K Oota; Y Hirata; F Marumo; I Kihara
Journal:  Exp Nephrol       Date:  1995 May-Jun

8.  N alpha-acetyl-[Arg8]vasopressin antagonizes the behavioral effect of [Cyt6]vasopressin-(5-9), but not of vasopressin.

Authors:  G L Kovács; B Liu; J P Burbach; J M Van Ree; D De Wied
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

9.  Regulation of angiotensin II type 1A receptor intracellular retention, degradation, and recycling by Rab5, Rab7, and Rab11 GTPases.

Authors:  Lianne B Dale; Jennifer L Seachrist; Andy V Babwah; Stephen S G Ferguson
Journal:  J Biol Chem       Date:  2004-01-07       Impact factor: 5.157

10.  Synthesis and biological activities of a fluorescent photoaffinity analog of vasopressin.

Authors:  A Buku; I L Schwartz; D Gazis; C L Ma; P Eggena
Journal:  Endocrinology       Date:  1985-07       Impact factor: 4.736

View more
  4 in total

Review 1.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

2.  Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin.

Authors:  Richard Bouley; Paula Nunes; Billy Andriopoulos; Margaret McLaughlin; Matthew J Webber; Herbert Y Lin; Jodie L Babitt; Thomas J Gardella; Dennis A Ausiello; Dennis Brown
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-12

3.  Large G protein α-subunit XLαs limits clathrin-mediated endocytosis and regulates tissue iron levels in vivo.

Authors:  Qing He; Richard Bouley; Zun Liu; Marc N Wein; Yan Zhu; Jordan M Spatz; Chia-Yu Wang; Paola Divieti Pajevic; Antonius Plagge; Jodie L Babitt; Murat Bastepe
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-23       Impact factor: 11.205

4.  Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin.

Authors:  Timothy N Feinstein; Naofumi Yui; Matthew J Webber; Vanessa L Wehbi; Hilary P Stevenson; J Darwin King; Kenneth R Hallows; Dennis Brown; Richard Bouley; Jean-Pierre Vilardaga
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.